Heron Therapeutics (HRTX) PT Lowered to $27 at Stifel, Keeps 'Buy' as Potential Positive FDA Label Talks
Tweet Send to a Friend
Stifel analyst Derek Archilia lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $27.00 (from $28.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
